Vulvar Lichen Sclerosus When Topical Steroids Have Not Achieved Resolution
This protocol covers the next step in managing vulvar lichen sclerosus when an initial course of ultra-potent or potent topical steroids applied to the genital skin has not achieved the expected resolution at the 3-month assessment.
Previous Treatment — Insufficient Response
First-line treatment with ultra-potent or potent topical steroids applied to the genital skin — including agents such as clobetasol propionate or mometasone furoate — did not result in resolution of lichen sclerosus when assessed after 3 months. Non-achievement of this goal is the criterion that escalates management to the next treatment line.
Next-Line Approach (Partial Overview)
The next step involves a topical calcineurin inhibitor applied to the affected vulval skin. The full protocol specifies the agent, the treatment course, and the criteria guiding selection.
Clinical Goal
The primary aim of this next-line treatment is improvement in vulval pruritus and burning/pain.
Full regimen details — agent selection, course duration, and sequencing — are in the complete structured protocol.
References
DOI: 10.1111/jdv.18102
- However, the efficacy of topical tacrolimus 0.1% in the treatment of vulval LS has been confirmed in a comparative randomised study.
- Topical tacrolimus 0.1% has also shown to be effective when used for 16 to 24 weeks in males and females with genital and extragenital LS.
- Comparing pimecrolimus 1% cream and clobetasol propionate 0.05% cream, both treatments showed improvement in pruritus and burning/pain after 12 weeks in vulval LS, but clobetasol was found to be superior in improving inflammation.
View source ↗